Placebo group:Placebo capsules

4 trials

Sponsors

Second Xiangya Hospital, Central South University., Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences, Peking Union Medical College, Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical College, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College

Conditions

Atopic dermatitisBipolar DisorderPemphigus

Early Phase 1

A randomized, double-blind, placebo-controlled, single center clinical trial of fecal microbiota transplantation in the treatment of moderate to severe atopic dermatitis

Active, not recruitingChiCTR2100047842

Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences, Peking Union Medical CollegeAtopic dermatitis

Start: 2021-07-01Updated: 2022-08-30

A randomized, double-blind, placebo-controlled, multi-center clinical trial of fecal microbiota transplantation in the treatment of moderate to severe atopic dermatitis

Active, not recruitingChiCTR2300072873

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical CollegeAtopic dermatitis

Start: 2023-07-01Updated: 2023-07-02

Phase 2

Fecal Microbiota Transplantation in the Treatment of Mild-to-moderate Active Pemphigus: A Randomized, Double-blind, Placebo-controlled, Clinical Trial

RecruitingChiCTR2200063544

Hospital for Skin Diseases(Institute of Dermatology)Chinese Academy of Medical Sciences and Peking Union Medical CollegePemphigus

Start: 2022-09-12Updated: 2023-08-07

Unknown Phase

The efficacy, safety and related mechanisms of bifidobacteria in the adjuvant treatment of bipolar disorder

Active, not recruitingChiCTR1900021379

Second Xiangya Hospital, Central South University.Bipolar Disorder

Start: 2019-03-01Updated: 2019-02-18

Related Papers

Osteoporosis and low bone mass among schizophrenia and bipolar disorder: A cross-sectional study with newly diagnosed, drug-naïve subjects.

2023-12-282 citations